GLP-1 receptor agonists in type 2 diabetes - NICE guidelines versus clinical practice

British Journal of Diabetes and Vascular Disease

Volumn 14, Issue 2, 2014, Pages 52-59

  Thong, Ken Y ^a   Gupta, Piya S ^b   Cull, Melissa L ^b   Adamson, Karen A ^c   Dove, David S ^d   Rowles, Susannah V ^e   Tarpey, Stephanie ^e   Duncan, Catriona ^f   Chalmers, John ^f   Harper, Roy ^g   McDonald, Paula ^g   Brennan, Ursula ^g   Walton, Chris ^h   Ryder, Robert E J ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^c ST JOHN'S HOSPITAL   (United Kingdom)

^d FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e PENNINE ACUTE HOSPITALS NHS TRUST   (United Kingdom)

^f VICTORIA HOSPITAL   (United Kingdom)

^g ULSTER HOSPITAL   (United Kingdom)

^h HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Exenatide; GLP 1 receptor agonist; Insulin; Liraglutide; Obesity; Thiazolidinedione; Type 2 diabetes

Indexed keywords

BIPHASIC INSULIN; EXENDIN 4; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; MEDICAL AUDIT; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; REVIEW; UNITED KINGDOM;

EID: 84963541910     PISSN: 14746514     EISSN: 17534305     Source Type: Journal    
DOI: 10.15277/bjdvd.2014.015     Document Type: Review

References (32)

1. European Medicines Agency. Byetta: EPAR - Summary for the public. 2009. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Summary-for-the-public/human/000698/WC500051840.pdf) (accessed January 2014).
2. European Medicines Agency. Victoza: EPAR - Summary for the public. 2009. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Summary-for-the-public/human/001026/WC500050013.pdf (accessed January 2014).
3. Russell-Jones D, Gough S. Recent advances in incretin-based therapies. Clin Endocrinol 2012;77:489-9. http://dx.doi.org/10.1111/j.1365-2265.2012.04483.x
4. National Institute for Health and Care Excellence. http://www.nice.org.uk/ (accessed January 2014).
5. NICE short clinical guideline 87. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. 2009. www.nice.org.uk/CG87short-guideline (accessed January 2014).
6. NICE technology appraisal guidance 203. Liraglutide for the treatment of type 2 diabetes. 2010. http://guidance.nice.org.uk/TA203 (accessed January 2014).
7. Sinha A, Rajan M, Hoerger T, Pogach L. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care 2010;33:695-700. http://dx.doi.org/10.2337/dc09-1488
8. Wilding JPH, Hardy K. Glucagon-like peptide-1 analogues for type 2 diabetes. BMJ 2011;342:d410. http://dx.doi.org/10.1136/bmj.d410
9. Woehl A, Evans M, Tetlow A P, McEwan P. Evaluation of the cost-effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom. Cardiovasc Diabetol 2008;7:24. http://dx.doi.org/10.1186/1475-2840-7-24
10. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14:1-248.
11. Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitaglitpin, all as add-on to metformin monotherapy in type 2 diabetes mellitus. Diabet Med 2012; 29:313-20. http://dx.doi.org/10.1111/j.1464-5491.2011.03429.x
12. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: National clinical guideline for management in primary and secondary care (update). London: Royal College of Physicians. 2008. http://guidance.nice.org.uk/CG66/Guidance/pdf/English (accessed 27 January 2014).
13. Shyangdan D, Cummins E, Royle P, Waugh N. Liraglutide for the treatment of type 2 diabetes. Health Technol Assess 2011;15:77-86.
14. Ryder REJ, Thong KY, Cull ML, et al. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Pract Diab Int 2010; 27:352-357b. http://dx.doi.org/10.1002/pdi.1522
15. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab 2011; 13:703-10. http://dx.doi.org/10.1111/j.1463-1326.2011.01393.x
16. European Medicines Agency. Byetta-H-C-698-II-29: EPAR - Assessment Report - Variation. 2012. http://www.ema.europa.eu/docs/en-GB/doc-ument-library/EPAR--Assessment-Report--Variation/human/000698/WC500128211.pdf (accessed January 2014).
17. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011;378: 169-81. http://dx.doi.org/10.1016/S0140-6736(11)60614-4
18. Thong KY, Jose B, Blann AD, et al. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Res Clin Pract 2011;93:e87-91. http://dx.doi.org/10.1016/j.diabres.2011.05.015
19. Thong KY, Ryder RE, Cull ML, et al. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide-1 (GLP1-) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Diabet Med 2012;29:690-2. http://dx.doi.org/10.1111/j.1464-5491.2011.03475.x
20. Ryder REJ, Sen-Gupta P, Thong KY, ABCD nationwide liraglutide audit contributors. Liraglutide is effective across a range of obese body mass indices; findings from the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit. Diabetologia 2012;55[Suppl1]: S330 (Poster 801).
21. Norris SL, Lee N, Thakurta S, Chan BK. Exenatide safety and efficacy: a systematic review. Diabet Med 2009;26:837-846. http://dx.doi.org/10.1111/j.1464-5491.2009.02790.x
22. Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012;14:77-82. http://dx.doi.org/10.1111/j.1463-1326.2011.01493.x
23. Gentilella R, Bianchi C, Rossi A, Rotella CM. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab 2009;11:544-56. http://dx.doi.org/10.1111/j.1463-1326.2008.01018.x
24. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78. http://dx.doi.org/10.1111/j.1464-5491.2009.02666.x
25. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373: 473-81. http://dx.doi.org/10.1016/S0140-6736(08)61246-5
26. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 MET+TZD). Diabetes Care 2009;32:1224-30. http://dx.doi.org/10.2337/dc08-2124
27. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomized controlled trial. Diabetologia 2009;52:2046-55. http://dx.doi.org/10.1007/s00125-009-1472-y
28. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47. http://dx.doi.org/10.1016/S0140-6736(09)60659-0
29. Rosenstock TR, Shenouda SK, Bergenstal RM, et al. Baseline factors associated with glycaemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012;35:955-58. http://dx.doi.org/10.2337/dc11-1434
30. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analy-sis of randomized clinical trials. Diabet Med 2010;27:309-17. http://dx.doi.org/10.1111/j.1464-5491.2010.02941.x
31. Deacon CF, Mannucci E, Ahrén B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as addon therapy to metformin in subjects with type 2 diabetes - a review and meta analysis. Diabetes Obes Metab 2012;14:762-67. http://dx.doi.org/10.1111/j.1463-1326.2012.01603.x
32. SIGN 116 Management of diabetes: A national clinical guideline. 2010. www.sign.ac.uk/pdf/sign116.pdf (accessed January 2014).